The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Omeract How to Get into the “Act”

Omeract How to Get into the “Act”

April 1, 2010 • By Peter Brooks, MD, Maarten Boers, MD,PhD, MSc, Lee S. Simon, MD, Vibeke Strand, MD,and Peter Tugwell, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The concept for OMERACT, or Outcome Measures in Rheumatology, was born from the American/European divide, with two of the authors (Drs. Boers and Tugwell) musing one evening on the fact that different outcome measures were used in rheumatoid arthritis (RA) clinical trials conducted on either side of the Atlantic. Several questions immediately came to mind: Why should different outcome measures exist? Could consensus be reached? Could a common set of measures be agreed on that would allow comparison between trials and use in meta-analyses?

You Might Also Like
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
  • A Few Acronyms and Indices in OMERACT
  • Rheumatology’s Divergent Thinkers
Explore This Issue
April 2010

The outcome of nearly 20 years of deliberation shows that striving for the “truth” in science can transcend those cultural and historic differences that can divide the world. OMERACTers can attest to the vigorous debates conducted at our conferences. Clearly, there is now a sense that consensus can be achieved on evidence presented and subjected to a fundamental screening process to ascertain utility. Thus, the OMERACT “filter” is an important guiding principle.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What Is the OMERACT Filter?

To be accepted as an OMERACT-endorsed outcome measure for use in a clinical trial, the measure must have been passed through the OMERACT filter in its intended setting.1 The filter has three component criteria: truth, discrimination, and feasibility. Each component criterion represents a question to be answered about that measure, in each of its intended settings.

  1. Truth: Is the measure truthful? Does it measure what it intends to measure? Is the result free of bias and is it clinically relevant? This criterion captures the issues of face, content, and criterion validity.
  2. Discrimination: Does the measure discriminate between situations that are of interest? These situations can be states at one time (for classification or progress) or states at different times (when measuring changes). This criterion captures the issues of reliability and sensitivity to change.
  3. Feasibility: Can the measure be applied easily, given the constraints of time, cost, and interpretability? This criterion addresses the practical reality of the use of the measure and is critical in determining the success (adoption) of the measure in the field.

TABLE 1

CONTENT

  • Ankylosing spondylitis (AS)
  • AS–reference case
  • Connective tissue disease–Interstitial lung disease
  • Fibromyalgia
  • Gout outcome measures
  • Hip and knee arthroplasty
  • Low back pain
  • Osteoarthritis
  • Osteoporosis
  • Psoriatic arthritis
  • Remission in RA
  • Systemic lupus erythematosus
  • Systemic sclerosis
  • Vasculitis

METHODS

  • Computerized adaptive testing and item response theory
  • Effective consumer
  • Equity
  • Fatigue
  • Flares in RA
  • Health economics
  • International Classification of Functioning, Disability and Health Literacy
  • MRI as an outcome measure in RA
  • MRI of the cervical spine
  • MRI in AS
  • MRI in idiopathic arthritis
  • Nonpharmalogical
  • Patient perspective
  • Psychosocial measures in musculoskeletal trials
  • Reevaluating response in RA
  • Responsiveness: Low disease activity
  • Responsiveness: Minimal clinically important difference
  • Responsiveness: Minimal clinically important improvement and patient acceptable symptom state

Safety

  • Single joint response
  • Soluble biomarkers
  • Surrogate outcome
  • Synovial tissue analysis in randomized controlled trials
  • Total articular replacement criteria
  • Ultrasound
  • Work productivity

How Does OMERACT Work?

OMERACT has five executives, with members from Australasia, Europe, and North America. Over the past few years, we have established solid relationships with the European League Against Rheumatism (EULAR) and the ACR, both of whom now contribute to the effort by providing fellowships to allow young rheumatology researchers to attend OMERACT meetings. Representatives of these organizations sit on OMERACT’s Scientific Advisory Committee that meets twice a year and also includes clinical investigators and opinion leaders from around the globe.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Legislation & Advocacy, Practice Management, Quality Assurance/Improvement, Rheumatoid Arthritis Tagged With: Clinical research, Diagnostic Criteria, OMERACT, Outcome measures, Outcome Measures in Rheumatology, OutcomesIssue: April 2010

You Might Also Like:
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
  • A Few Acronyms and Indices in OMERACT
  • Rheumatology’s Divergent Thinkers
  • Patients Add Power to Research Initiatives

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)